StemCells, Inc. Announces Strategic Realignment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
StemCells (STEM) PT Cut to $3 at Maxim Group
December 23, 2015 12:18 PM ESTMaxim Group analyst Jason Kolbert lowered his price target on StemCells (NASDAQ: STEM) to $3.00 (from $5.00) but maintained a Buy rating after the company suspended the phase II AMD (Radiant) study to focus on the spinal cord injury (SCI) trial.
Stem's management announced the decision to focus on the spinal cord injury (SCI) trial. Management will suspend the company's phase II AMD (Radiant)... MoreUPDATE: StemCells (STEM) Declines After Shares Resume Trading
December 23, 2015 8:10 AM EST(Updated - December 23, 2015 8:16 AM EST)
StemCells (NASDAQ: STEM) Declines After Shares Resume Trading
... More